Table 2 Clinical characteristics of COVID-19 patients without and with de novo bronchiectasis included in the study
From: Prevalence and early outcome of bronchiectasis as an atypical presentation in COVID-19 patients
COVID-19 without bronchiectasis (n = 400) | COVID-19 with de novo bronchiectasis (n = 14) | P | |
|---|---|---|---|
Cough | 338 (84.5%) | 14 (100%) | 0.33 |
Cough score | 3.05 ± 1.88 | 4.93 ± 0.27 | < 0.001 |
Sputum | < 0.001 | ||
None | 309 (77.3%) | 2 (14.3%) | |
Whitish | 16 (4%) | 1 (1.7%) | |
Colored | 75 (18.8%) | 11 (72.7%) | |
Blood tinged | 0 | 0 | |
Dyspnea | 294 (73.5%) | 13 (92.9%) | 0.08 |
mMRC score | 0.04 | ||
0 | 137 (34.3%) | 1 (7.1%) | |
1 | 5 (1.3%) | 0 | |
2 | 53 (13.3%) | 0 | |
3 | 4 (1%) | 0 | |
4 | 201 (50.2%) | 13 (92.9%) | |
Fatigue | 393 (98.3%) | 14 (100%) | 0.78 |
Sore throat | 123 (30.8%) | 3 (21.4%) | 0.33 |
Cyanosis | 199 (49.8%) | 10 (71.4%) | 0.09 |
Respiratory distress | 56 (14%) | 7 (50%) | < 0.001 |
Respiratory failure | 198 (49.5%) | 11 (78.6%) | 0.02 |